Genetic factors affecting patient responses to pancreatic cancer treatment

Authors George Fotopoulos, Konstantinos Syrigos, Muhammad Wasif Saif.


Cancer of the exocrine pancreas is a malignancy with a high lethal rate. Surgical resection is the only possible curative mode of treatment. Metastatic pancreatic cancer is incurable with modest results from the current treatment options. New genomic information could prove treatment efficacy. An independent review of PubMed and ScienceDirect databases was performed up to March 2016, using combinations of terms such pancreatic exocrine cancer, chemotherapy, genomic profile, pancreatic cancer pharmacogenomics, genomics, molecular pancreatic pathogenesis, and targeted therapy. Recent genetic studies have identified new markers and therapeutic targets. Our current knowledge of pancreatic cancer genetics must be further advanced to elucidate the molecular basis and pathogenesis of the disease, improve the accuracy of diagnosis, and guide tailor-made therapies.

Keywords Chemotherapy, genomics, molecular pancreatic pathogenesis, pancreatic exocrine cancer, targeted therapy

Ann Gastroenterol 2016; 29 (4): 466-476

Review Articles